This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Research » Insulin

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

Scientific Peer Review of Research Applications for the Department of Defense - Andrew P. Mandell

Posted: Thursday, August 06, 2009

Diabetes advocate, Andrew P. Mandell, MR. DIABETES® and Executive Director of Defeat Diabetes Foundation, Inc., recently participated in the evaluation of research proposals submitted to the Peer Reviewed Medical Research Program (PRMRP) sponsored by the Department of Defense.

Study Finds Intensive Glucose Control Halves Complications of Longstanding Type 1 Diabetes -- Improved Long-Term Outlook

Posted: Wednesday, July 29, 2009

Near-normal control of glucose beginning as soon as possible after diagnosis would greatly improve the long-term prognosis of Type 1 diabetes, concludes a study published in the July 27, 2009, issue of the Archives of Internal Medicine, which updates information about the clinical course of Type 1 diabetes.

Researchers Implant Pig Cells in Type 1 Diabetics

Posted: Wednesday, July 29, 2009

A New Zealand biotech company began a trial last week that implanted cells from newborn pigs into eight human volunteers as an experimental treatment for their diabetes and the participants will not use immunosuppressant drugs.

A Step Closer to Regenerating Beta Cells

Posted: Wednesday, July 22, 2009

US scientists have come a step closer to finding a way to help treat people with diabetes by reactivating their own insulin-producing beta cells in the pancreas. They discovered a hitherto unknown role for a well known protein: it helps immature endocrine systems generate new pancreatic islet cells, which include the insulin-producing beta cells.

New Once-daily Treatment for Type 2 Diabetes

Posted: Wednesday, July 15, 2009

A new treatment for Type 2 diabetes may soon be a reality in the U.S.. Liraglutide (Victoza), a once-daily injectable treatment for Type 2 diabetes, is pharmaceutical company Novo Nordisk's latest brain child and has been approved by the E.U.

Lantus Insulin: Link to Cancer Shaky - Update

Posted: Wednesday, July 08, 2009

There is conflicting data over possible cancer risk from Lantus Insulin, but another alternative exists that can reduce your risk of cancer.

Lantus Insulin: A Possible Link with Cancer - Requires Further Investigation

Posted: Tuesday, June 30, 2009

Just as in the Accord study and in the Avandia debacle controversy, premature release of this kind of information before all the facts are in can be devastating for the medical community and patients. They will tell patients to consult with their physicans before making any changes to their treatment. But what can their physician tell them when they have not had any time to analyze the data and the information is not conclusive and more studies are needed?

This premature release states that Sanofi-Aventis's diabetes drug Lantus may increase the risk of cancer, according to European studies involving some 300,000 insulin-treated patients, prompting a call from experts for more research.

Gene Inhibition Helps to Normalize Type 2 Diabetes

Posted: Tuesday, June 30, 2009

In research that could lead to new approaches for the treatment of Type 2 diabetes, a research team has found that suppressing a liver enzyme that induces glucose production helped diminish the symptoms of the disease — reducing blood glucose concentrations, decreasing rates of glucose production in the liver, and improving insulin sensitivity.

Using Vitamin C Plus Insulin to Stop Diabetes Damage

Posted: Wednesday, June 24, 2009

Researchers have found a way to stop the damage caused by Type 1 diabetes with the combination of insulin and a common vitamin found in most medicine cabinets. This simply means that getting your glucose under control is not enough.

Inhaled Insulin AFRESA(R) Controls Post-Meal Sugar Levels with Less Weight Gain and Hypoglycemia

Posted: Wednesday, June 17, 2009

The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia for adult patients with diabetes.